Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Blood Adv. 2022 Mar 22;6(6):1919-1931. doi: 10.1182/bloodadvances.2021006189.
Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling (n = 88), CIBERSORT, and multiplex immunohistochemistry (n = 131) to characterize the immunoprofile of cHL TME and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and -noninflamed TME. Several macrophage-related genes were upregulated in samples with the non-T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages. A cluster with high proportions of checkpoint protein (programmed cell death protein 1, PD-1 ligands, indoleamine 2,3 dioxygenase 1, lymphocyte-activation gene 3, and T-cell immunoglobulin and mucin domain containing protein 3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs 96%; P = .010) and remained an independent prognostic factor for OS in multivariable analysis (HR, 4.34; 95% CI, 1.05-17.91; P = .043). cHL samples with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples (P < .001) and in an expansion cohort of 84 cHL relapse samples (P = .048). Our findings demonstrate the impact of T cell- and macrophage-mediated checkpoint system on the survival of patients with cHL.
越来越多的证据表明,肿瘤微环境(TME)和免疫逃逸在经典霍奇金淋巴瘤(cHL)的发病机制和临床过程中起着重要作用。我们使用基因表达谱分析(n = 88)、CIBERSORT 和多重免疫组化(n = 131)来描述 cHL TME 的免疫特征,并将这些发现与生存相关联。基因表达分析将肿瘤分为 T 细胞炎症和非炎症 TME 亚组。在非 T 细胞炎症 TME 样本中,几种巨噬细胞相关基因上调,根据免疫细胞比例,样本根据 T 细胞和巨噬细胞的含量聚类。一个具有高比例检查点蛋白(程序性细胞死亡蛋白 1、PD-1 配体、吲哚胺 2,3 双加氧酶 1、淋巴细胞激活基因 3、T 细胞免疫球蛋白和粘蛋白结构域蛋白 3)阳性免疫细胞的簇与不良的总生存(OS)相关(5 年 OS 为 76%对 96%;P =.010),并在多变量分析中仍然是 OS 的独立预后因素(HR,4.34;95%CI,1.05-17.91;P =.043)。cHL 样本中高比例的检查点蛋白过表达基因编码细胞毒性因子,这表明它们具有免疫活性,这似乎有些矛盾。在 290 例诊断性 cHL 样本的验证队列中(P <.001)和在 84 例 cHL 复发样本的扩展队列中(P =.048),这种检查点分子基因特征与生存不良相关。我们的研究结果表明,T 细胞和巨噬细胞介导的检查点系统对 cHL 患者的生存有影响。